ArticlePLoS biology2025
The blood-brain barrier regulates brain tumor growth through the SLC36 amino acid transporter Pathetic in Drosophila.
Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumour-driven lipid accumulation in oenocytes reflects systemic lipid alterations.PLoS genetics · 2026Article
- Integrative Multi-Omics Analysis Reveals the Characteristic Metabolic Signature of Glioma and Enables Plasma-Based Liquid Biopsy.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tumors adapt their metabolism to sustain increased proliferation, rendering them particularly vulnerable to fluctuations in nutrient availability. However, the role of the tumor microenvironment in modulating sensitivity to nutrient restriction (NR) remains poorly understood. Using a Drosophila brain dedifferentiation neural stem cell (NSC) tumor model induced by Prospero (Pros) inhibition, we show that tumor sensitivity to NR is governed by the blood-brain barrier (BBB) glia. We found that the SLC36 amino acid transporter Pathetic (Path) regulates brain branched-chain amino acids (BCAAs) levels. Under NR, while wild-type buffers against low nutrient levels by upregulating Path, tumor glia down-regulate Path. Furthermore, Path is specifically required by the tumor (but not wildtype) BBB; its downregulation causes reduced cell cycle progression of BBB glial cells and, in turn, restricts NSC tumor growth. Path influences BBB glial cell cycle via the BCAA-mTor-S6K pathway, and its expression is controlled by Ilp6 levels and the Insulin/PI3K pathway. Overexpression of Path is sufficient to counteract the inhibitory effects of NR on tumor growth. These findings suggest that Path levels at the glial niche BBB play a key role in determining tumor sensitivity to NR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.